![Karin Ann Thacker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Karin Ann Thacker formerly worked at Puma Biotechnology, Inc., as Senior Director & Head-Regulatory Development from 2015 to 2016, Harpoon Therapeutics, Inc., as VP-Regulatory Affairs & Quality Assurance from 2020 to 2022, Gritstone bio, Inc., as Vice President-Global Regulatory Affairs from 2019 to 2020, and Senti Biosciences, Inc., as Vice President-Quality & Regulatory Affairs.
Ms. Thacker received her undergraduate degree and graduate degree from the University of Manitoba.
Former positions of Karin Ann Thacker
| Companies | Position | End |
|---|---|---|
Senti Biosciences, Inc.
 Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | General Counsel | 30/04/2024 |
| HARPOON THERAPEUTICS, INC. | General Counsel | 31/07/2022 |
| GRITSTONE BIO, INC. | General Counsel | 31/07/2020 |
| PUMA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 30/04/2016 |
Training of Karin Ann Thacker
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
8
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
University of Manitoba
 University of Manitoba Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Puma Biotechnology, Inc.
 Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Gritstone bio, Inc.
 Gritstone bio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for cancer | Health Technology |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immunotherapy company that develops T-cell engagers to treat cancer and other diseases | Health Technology |
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Health Technology |
- Stock Market
- Insiders
- Karin Ann Thacker
